Non-alcoholic Fatty Liver Disease (MASLD), Non-alcoholic Steatohepatitis (MASH)
Conditions
Brief summary
The purpose of this study is to better understand the main barriers to earlier diagnosis and better management of MASLD/MASH patients and to understand the key barriers to adoption of guidelines. This study is a cross-sectional design, conducted across 5 countries in Europe- France, Germany, Spain, United Kingdom (UK), Italy. Study participants, Hepatologists and other metabolically focused healthcare providers (HCPs), will be recruited to complete a 15 minute self-administered online survey.
Interventions
OTHERNo treatment given
No treatment given
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
For Hepatologists: 1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age above or equal to 18 years at the time of signing informed consent. 3. Is a physician 4. Lives in UK, France, Germany, Italy or Spain 5. Primary medical specialty is: 5.a. Hepatology or 5.b. Gastroenterology or Internal Medicine with a subspecialty in Hepatology 6. In practice at least 3 years 7. Spends at least 50 percent of their time in an office/clinic setting 8. Spends at least 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with MASH/MASLD For Metabolically-Focused HCPs (Endocrinologist/General Physician/Family Physician/Internal Medicine): 1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age above or equal to 18 years at the time of signing informed consent. 3. Is a physician 4. Lives in UK, France, Germany, Italy or Spain 5. Primary medical specialty is: 5.a. General Physician/Family Practitioner or Endocrinology or 5.b. Internal Medicine without subspecialty in Hepatology 6. In practice at least 3 years 7. Spends less than 50 percent of their time in an office/clinic setting 8. Spends less than 60 percent of their time in direct patient care 9. Sees at least 15 patients/month with suspected/diagnosed MASH/MASLD 10. Sees and actively treats at least 30 patients/month with Type 2 Diabetes (T2D) and/or Obesity
Exclusion criteria
1. Previous participation in this study. Participation is defined as having given informed consent in this study 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation 3. Does not meet inclusion criteria requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Unaided awareness | At the time of survey response (Day 1) | Open ended response |
| Aided awareness | At the time of survey response (Day 1) | Multi- select from defined list |
| Behaviours relative to diagnosing and managing MASLD | At the time of survey response (Day 1) | Numerical, multi-select from defined list |
| Use of current guidelines | At the time of survey response (Day 1) | Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Not at all Relevant, 7=Extremely Relevant |
| Barriers in guideline adoption | At the time of survey response (Day 1) | Multi-select from defined list; Likert scales; Numerical Likert scales: 1=Doesn't impact at all, 7=Greatly impacts |
Countries
India
Outcome results
None listed